HRP20030592B1 - Compositions of estrogen-cyclodextrin complexes - Google Patents

Compositions of estrogen-cyclodextrin complexes

Info

Publication number
HRP20030592B1
HRP20030592B1 HR20030592A HRP20030592A HRP20030592B1 HR P20030592 B1 HRP20030592 B1 HR P20030592B1 HR 20030592 A HR20030592 A HR 20030592A HR P20030592 A HRP20030592 A HR P20030592A HR P20030592 B1 HRP20030592 B1 HR P20030592B1
Authority
HR
Croatia
Prior art keywords
estrogen
compositions
cyclodextrin complexes
granulate
present
Prior art date
Application number
HR20030592A
Other languages
English (en)
Croatian (hr)
Inventor
Backensfeld Thomas
Heil Wolfgang
Lipp Ralph
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of HRP20030592A2 publication Critical patent/HRP20030592A2/hr
Publication of HRP20030592B1 publication Critical patent/HRP20030592B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Medical Informatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Materials Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
HR20030592A 2000-12-20 2003-07-21 Compositions of estrogen-cyclodextrin complexes HRP20030592B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25648400P 2000-12-20 2000-12-20
EP00610135A EP1216713A1 (en) 2000-12-20 2000-12-20 Compositions of estrogen-cyclodextrin complexes
PCT/IB2001/002605 WO2002049675A1 (en) 2000-12-20 2001-12-20 Compositions of estrogen-cyclodextrin complexes

Publications (2)

Publication Number Publication Date
HRP20030592A2 HRP20030592A2 (en) 2005-06-30
HRP20030592B1 true HRP20030592B1 (en) 2007-05-31

Family

ID=26073713

Family Applications (2)

Application Number Title Priority Date Filing Date
HR20030592A HRP20030592B1 (en) 2000-12-20 2003-07-21 Compositions of estrogen-cyclodextrin complexes
HRP20070198AA HRP20070198B1 (hr) 2000-12-20 2007-05-08 Smjese estrogen-ciklodekstrin kompleksa

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20070198AA HRP20070198B1 (hr) 2000-12-20 2007-05-08 Smjese estrogen-ciklodekstrin kompleksa

Country Status (30)

Country Link
US (3) US6958326B2 (hu)
EP (3) EP1216713A1 (hu)
JP (2) JP4782364B2 (hu)
KR (3) KR20030070905A (hu)
CN (1) CN1268396C (hu)
AT (1) ATE311204T1 (hu)
AU (3) AU1941802A (hu)
BG (1) BG66050B1 (hu)
BR (1) BRPI0116417B8 (hu)
CA (2) CA2756207C (hu)
CY (2) CY1106071T1 (hu)
CZ (2) CZ305671B6 (hu)
DE (1) DE60115499T2 (hu)
DK (2) DK1353700T3 (hu)
EA (2) EA007411B1 (hu)
EE (1) EE05282B1 (hu)
ES (2) ES2639537T3 (hu)
HK (1) HK1055397A1 (hu)
HR (2) HRP20030592B1 (hu)
HU (2) HU230745B1 (hu)
IL (3) IL156437A0 (hu)
LT (1) LT1632237T (hu)
ME (1) MEP38108A (hu)
MX (1) MXPA03005636A (hu)
NO (1) NO332726B1 (hu)
NZ (1) NZ526847A (hu)
RS (2) RS57801B1 (hu)
SI (2) SI1632237T1 (hu)
SK (1) SK287500B6 (hu)
WO (1) WO2002049675A1 (hu)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US6992075B2 (en) * 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
US7790201B2 (en) 2003-09-03 2010-09-07 Mallinckrodt Inc. Granular sustained release preparation and production thereof
US8022053B2 (en) 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
US20070287684A1 (en) 2006-05-22 2007-12-13 Irshad Chaudry Methods and compositions for treating trauma-hemorrhage using estrogen and derivatives thereof
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
PL1886694T3 (pl) * 2006-08-10 2009-11-30 Jenapharm Gmbh Doustna postać leku do antykoncepcji
HUP0700826A3 (en) * 2007-12-20 2010-03-29 Richter Gedeon Nyrt Coated tablet containing drospirenone and process for producing the same
US20090269403A1 (en) * 2008-04-24 2009-10-29 Shaked Ze Ev Oral contraceptive dosage forms and methods of making such dosage forms
US8735374B2 (en) * 2009-07-31 2014-05-27 Intelgenx Corp. Oral mucoadhesive dosage form
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
BR112012026115B1 (pt) 2010-04-15 2019-12-24 Bayer Ip Gmbh forma de dosagem oral sólida, seu uso, e unidade de acondicionamento
US20130140210A1 (en) 2010-04-15 2013-06-06 Bayer Intellectual Property Gmbh Low-dosed solid oral dosage forms for hrt
WO2012120365A1 (en) 2011-03-07 2012-09-13 Aurobindo Pharma Limited Stable pharmaceutical composition comprising ethinyl estradiol
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
US8586527B2 (en) 2011-10-20 2013-11-19 Jaipal Singh Cerivastatin to treat pulmonary disorders
CN102512688A (zh) * 2011-12-29 2012-06-27 上海新华联制药有限公司 尼尔雌醇-β-环糊精包合物及制剂和制备方法
PL2806877T3 (pl) 2012-01-23 2020-06-01 Sage Therapeutics, Inc. Formulacje neuroaktywnego steroidu zawierające kompleks allopregnanolonu i eteru sulfobutylowego beta-cyklodekstryny
RU2494757C1 (ru) * 2012-04-12 2013-10-10 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая фермент дезоксирибонуклеазу, альфа-фетопротеин и глицирризиновую кислоту или ее соли: глицирризинат аммония, или дикалия, или тринатрия
WO2013172969A1 (en) 2012-05-15 2013-11-21 The Uab Research Foundation Methods and compositions for treating trauma-hemorrhage using estrogen and derivatives thereof
EP3957309A1 (en) 2012-08-21 2022-02-23 Sage Therapeutics, Inc. Preparation of a composition comprising allopregnanolone and sulfobutylether-beta-cyclodextrin
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
NO3106148T3 (hu) 2015-06-18 2018-08-11
MA45276A (fr) 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
WO2016203009A1 (en) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Orodispersible tablet containing estetrol
GEP20217243B (en) 2015-06-18 2021-04-26 Sprl Estetra Orodispersible dosage unit containing an estetrol component
HUE054551T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Ösztetrolt tartalmazó, szájban diszpergálódó tabletta
RU2640081C1 (ru) * 2016-07-11 2017-12-26 Общество с ограниченной ответственностью "ЛАЙФ САЙНСЕС ОХФК" Фармацевтическая композиция и лекарственное средство на основе клатратного комплекса N-карбамоилметил-4-фенил-2-пирролидон или 4-фенилпирацетам с циклодекстрином, способы его получения (варианты)
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
EP3666260A1 (en) * 2018-12-13 2020-06-17 Laboratorios Leon Farma SA Ethinyl estradiol-beta-cyclodextrin complex and process for preparing thereof
CN114225050B (zh) * 2022-01-29 2022-12-13 国家卫生健康委科学技术研究所 炔雌醇环糊精复合物的制备及应用
CN116617157A (zh) * 2023-05-25 2023-08-22 国家卫生健康委科学技术研究所 一种制备pH响应性炔雌醇复合水凝胶的方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4154820A (en) * 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
DE2652761C2 (de) 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
JPS5527558A (en) * 1978-08-18 1980-02-27 Tokico Ltd Gas spring
HU190356B (en) 1981-10-27 1986-08-28 Richter Gedeon Vegyeszeti Termekek Gyara Rt,Hu Process for preparing steroid-gamma-cyclodextrin inclusion complexes with high water-solubility
US4383992A (en) 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4727077A (en) 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
US4877774A (en) 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
NL8801670A (nl) * 1988-07-01 1990-02-01 Walter Adrianus Josephus Johan Farmaceutisch preparaat.
US5229370A (en) 1988-08-15 1993-07-20 Ammeraal Robert N Water soluble branched beta cyclodextrin steroid complex
DE3916112A1 (de) 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
US4978532A (en) 1989-08-11 1990-12-18 Pharmedic Co. Dosage form for administration of dehydroepiandrosterone
JP3207212B2 (ja) 1991-03-01 2001-09-10 久光製薬株式会社 吸収促進剤およびこれを含有する外用剤
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
DE4426709A1 (de) 1994-07-20 1996-01-25 Schering Ag Steroidale Sexualhormone enthaltende feste Arzneiformen
BR9509019B1 (pt) * 1994-09-22 2009-01-13 comprimido isento de solventes orgÂnicos.
JP2920611B2 (ja) 1995-12-11 1999-07-19 株式会社シーエーシー 皮膚炎の治療外用剤
ES2223081T3 (es) * 1996-07-26 2005-02-16 Wyeth Metodo anticonceptivo oral monofasico y kit que comprende una combinacion de progestina y estrogeno.
WO1998007414A1 (en) * 1996-08-22 1998-02-26 Research Triangle Pharmaceuticals Ltd. Compositions comprising microparticles of water-insoluble substances and method for preparing same
DE19652196A1 (de) * 1996-12-16 1998-06-18 Jenapharm Gmbh Homogene steroidhaltige Präformulierungen zur Herstellung niedrigdosierter fester und halbfester pharmazeutischer Zubereitungen
DE19654609A1 (de) * 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
DE19848303A1 (de) * 1998-10-14 2000-04-20 Schering Ag Kombination aus Gestagenen und Zuckern
ATE257332T1 (de) * 1999-03-18 2004-01-15 Bristol Myers Squibb Co Vitamin formulierung für kardiovaskuläre gesundheit
JP2000336032A (ja) * 1999-05-26 2000-12-05 Kissei Pharmaceut Co Ltd ピペラジンアセトアミド誘導体を含有する徐放性経口医薬品組成物
NZ517845A (en) * 1999-08-31 2004-12-24 Schering Ag Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
CN101934078A (zh) * 2000-01-18 2011-01-05 拜耳先灵医药股份有限公司 包含屈螺酮和雌激素的药物组合物及其应用

Also Published As

Publication number Publication date
DK1353700T3 (da) 2006-03-20
EA011275B1 (ru) 2009-02-27
ES2249387T3 (es) 2006-04-01
EE05282B1 (et) 2010-04-15
IL156437A (en) 2008-03-20
IL188250A0 (en) 2008-03-20
EP1216713A1 (en) 2002-06-26
JP2009102424A (ja) 2009-05-14
HUP1500492A2 (en) 2003-11-28
CY1119806T1 (el) 2018-06-27
AU2006225232B2 (en) 2007-09-27
US20070093451A1 (en) 2007-04-26
BG108002A (bg) 2004-08-31
RS50362B (sr) 2009-11-10
LT1632237T (lt) 2017-10-10
DK1632237T3 (en) 2017-09-25
RS20090299A (en) 2009-11-10
HRP20070198A2 (en) 2007-09-30
CZ2015831A3 (hu) 2003-11-12
AU2006225232A1 (en) 2006-10-26
NO20032805L (no) 2003-08-20
EE200300298A (et) 2003-12-15
CY1106071T1 (el) 2011-06-08
CA2432151A1 (en) 2002-06-27
BRPI0116417B1 (pt) 2019-04-02
NO20032805D0 (no) 2003-06-19
NO332726B1 (no) 2012-12-27
BG66050B1 (bg) 2010-12-30
HK1055397A1 (en) 2004-01-09
AU1941802A (en) 2002-07-01
MEP38108A (en) 2011-02-10
CZ20031985A3 (cs) 2003-11-12
CA2756207A1 (en) 2002-06-27
RS57801B1 (sr) 2018-12-31
JP2004518656A (ja) 2004-06-24
BR0116417A (pt) 2003-12-30
MXPA03005636A (es) 2003-10-06
AU2002219418B2 (en) 2006-07-06
YU51203A (sh) 2006-08-17
HUP0302499A2 (hu) 2003-11-28
CN1268396C (zh) 2006-08-09
IL156437A0 (en) 2004-01-04
HRP20070198B1 (hr) 2019-04-19
EP1632237B1 (en) 2017-06-21
EP1632237A3 (en) 2006-04-12
ATE311204T1 (de) 2005-12-15
IL188250A (en) 2012-02-29
DE60115499T2 (de) 2006-08-10
CA2756207C (en) 2014-02-11
AU2002219418C1 (en) 2002-07-01
WO2002049675A1 (en) 2002-06-27
CN1482921A (zh) 2004-03-17
KR101275372B1 (ko) 2013-06-14
EP1353700A1 (en) 2003-10-22
ES2639537T3 (es) 2017-10-27
KR20030070905A (ko) 2003-09-02
DE60115499D1 (de) 2006-01-05
US6958326B2 (en) 2005-10-25
PL361799A1 (en) 2004-10-04
AU2006225232B8 (en) 2007-11-15
EP1632237A2 (en) 2006-03-08
EA200600884A1 (ru) 2006-10-27
KR20080108161A (ko) 2008-12-11
KR20090120015A (ko) 2009-11-23
BRPI0116417B8 (pt) 2021-05-25
CZ305671B6 (cs) 2016-02-03
SI1353700T1 (sl) 2006-02-28
NZ526847A (en) 2005-01-28
CZ307876B6 (cs) 2019-07-10
HUP0302499A3 (en) 2012-02-28
EP1353700B1 (en) 2005-11-30
US20020173487A1 (en) 2002-11-21
HU230745B1 (hu) 2018-01-29
SK287500B6 (sk) 2010-12-07
EA007411B1 (ru) 2006-10-27
US20050182024A1 (en) 2005-08-18
EA200300669A1 (ru) 2004-02-26
US7569557B2 (en) 2009-08-04
JP4782364B2 (ja) 2011-09-28
CA2432151C (en) 2012-01-24
SI1632237T1 (sl) 2017-10-30
US7163931B2 (en) 2007-01-16
SK9142003A3 (en) 2004-03-02
JP5015976B2 (ja) 2012-09-05
HRP20030592A2 (en) 2005-06-30
HU230299B1 (hu) 2015-12-28

Similar Documents

Publication Publication Date Title
HRP20030592B1 (en) Compositions of estrogen-cyclodextrin complexes
ATE350072T1 (de) Parfümzusammensetzungen
DK1157037T3 (da) GCSF-konjugater
DE69716435D1 (de) Xanthangummi enthaltende saure reinigungsmittel
ATE468126T1 (de) Ingwer-extraktzubereitung
ATE460921T1 (de) Medikamenthaltige zusammensetzung in aerosolform
YU87101A (sh) Derivati benzena, postupak za njihovo dobijanje i farmaceutski preparati koji ih sadrže
AP2002002674A0 (en) Clear Aqueous Anaesthetic composition.
BR0214602A (pt) Método de produção de um tablete detergente, tablete detergente, e, componente de argila adequado para uso em uma formulação detergente
EE04197B1 (et) Kütuselisandi kompositsioon
BR0109139B1 (pt) composiÇÕes farmacÊuticas incluindo alginatos
NO994937D0 (no) Krympingsreduserende middel for sementsammensetninger
DE60001366D1 (de) Orale zusammensetzung enthaltend perlit
BR0006230A (pt) Composição compreendendo ácido ascórbico epectina
BR9916537A (pt) Composição de fragrância, produto, uso de camonal, ciprisato, elintaal e/ou dispirona, e, processo para aumentar as propriedades de redução do malodor de uma composição de fragrância
DE69501183D1 (de) Feste orale pharmazeutische Zubereitung mit Gemfibrozil als aktiver Inhaltsstoff und Verfahren zur Herstellung
NO20012373D0 (no) Spröyteblanding inneholdende amfoterisk materiale for å redusere vonde lukter
AR015344A1 (es) Una composicion de agregado detergente en particulas que fluye libremente que contiene surfactante no ionico
DE60222236D1 (de) Zubereitungen enthaltend cyclohexamantan
ME00293B (me) Sastavi estrogen-ciklodekstrin kompleksa
ITMI931902A1 (it) Composizioni estinguenti e loro uso per il flooding
JP2007021138A (ja) 界面活性剤
ECSP993133A (es) Nueva composicion oral compactada que comprende derivados de catecol
RU99115876A (ru) Тормозная жидкость

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
PNAN Change of the applicant name, address/residence

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE

PNAN Change of the applicant name, address/residence

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT, DE

PPPP Transfer of rights

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

ODRP Renewal fee for the maintenance of a patent

Payment date: 20181129

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20191202

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20201216

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20211220